HLS:CC News and Press, HLS Therapeutics Inc. From 04/08/24

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada NewsWire Findings Presented on VASCEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels Lp...

Nexus Industrial REIT (NXR.UN:CA) is expected to report $0.19 for Q4 2023 Flagship Communities Real Estate Investment Trust (MHC.U:CA) is expected to report $0.4 for Q4 2023 Bridgemarq Real Estate Services Inc. Restricted Voting Shares (BRE:CA) is expected to report for quarter end 2023-1...

HLS Therapeutics Announces Fiscal 2023 Financial Results Canada NewsWire TORONTO , March 14, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorde...

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call Canada NewsWire TORONTO , Feb. 29, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2023 financial results o...

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan Canada NewsWire Public reimbursement for Vascepa is now available in Ontario , Quebec , British Columbia , Saskatchewan , New Brunswick , Northwest Territori...

HLS Therapeutics Announces CFO Departure Canada NewsWire John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson TORONTO , Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical co...

2023-12-11 19:00:00 ET Before a certain global health crisis hit the markets, it seemed that everyone was investing in the energy, tech, and financial services industries. As world economies almost came to an abrupt halt amid COVID-19, stocks in other areas of the economy came to th...

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline Canada NewsWire Analysis Also Found ...

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid Canada NewsWire TORONTO , Nov. 9, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet...

K-Bro Linen Inc. (KBL:CA) is expected to report $0.57 for Q3 2023 Yellow Pages Limited (Y:CA) is expected to report for Q3 2023 Ascot Resources Ltd. (AOT:CA) is expected to report for Q3 2023 Park Lawn Corporation (PLC:CA) is expected to report $0.27 for Q3 2023 Hut 8 Mining Corp....